Pure Global AI
NCT06355609Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

A Perspective Observation Phase II, Single-Arm Study Evaluating the 1st Line Efficacy and Safety of Sunvozertinib Plus Anlotinib in EGFR-Sensitive Mutations Combined With Co-Mutations Locally Advanced or Metastatic NSCLC
Hunan Province Tumor HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
sunvozertinib in combination with Anlotinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hunan Province Tumor Hospital
Location
Changsha, China
Timeline & enrollment
Phase
Phase 2
Start date
Apr 30, 2024
End date
Dec 30, 2027
Enrollment
100 participants
Primary outcome

Progression-free survival (PFS)

Summary

This is a phase II, open-label, single-arm, single-center clinical study to evaluate the
 preliminary efficacy of sunvozertinib in combination with anlotinib in patients with
 EGFR-sensitive mutations and co-mutations in locally advanced or metastatic treatment-naive
 non-small cell lung cancer.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06355609
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06355609 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hunan Province Tumor Hospital and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.